4 research outputs found
Nachrichten aus der BrĆ¼der-Gemeine, 1834, no. 04
The Moravian Church's monthly journal of its worldwide activities, including in Labrador, published from 1819-94
MOESM1 of SP, CGRP changes in pyridoxine induced neuropathic dogs with nerve growth factor gene therapy
Additional file 1: Figure S1. Nerve growth factor (NGF) immunostaining of the dorsal root ganglion (DRG) in the vehicle-treated (A), and NGF gene-treated (B) groups at 4Ā weeks after 1Ā week of pyridoxine injection. In the vehicle-treated group, NGF immunoreactive neurons are not detectable in the DRG. In the NGF gene-treated group, NGF immunoreactive neurons are abundantly observed in the DRG. Scale barĀ =Ā 50Ā Ī¼m
Additional file 1: Figure S1. of Sac-1004, a vascular leakage blocker, reduces cerebral ischemiaāreperfusion injury by suppressing bloodābrain barrier disruption and inflammation
Sac-1004 increases HBMEC survival. HBMECs were starved and treated with various concentrations of Sac-1004. Chemical structure of Sac-1004 (A). Cell survival was detected using an MTT assay (B). Under the same experimental conditions, cell viability was also determined by microscopy after incubation for 48Ā h (C). All data are presented the meansāĀ±āSEM. ***Pā<ā0.001. (JPG 82 kb
Additional file 1: Table S1. of Efficient strategy for the molecular diagnosis of intractable early-onset epilepsy using targeted gene sequencing
List of 172 targeted genes included in the epilepsy panel. Table S2. Clinical and demographic information of the patients. Table S3. Quality control matrices of NGS test results for all patients in this study. Table S4. Diagnostic yield of targeted NGS according to types of epilepsy syndrome. Table S5. Clinical factors associated with genetic abnormalities. (XLSX 31 kb